Travere Therapeutics Inc (NASDAQ: TVTX) on Tuesday, soared 5.03% from the previous trading day, before settling in for the closing price of $34.38. Within the past 52 weeks, TVTX’s price has moved between $12.91 and $36.15.
During the last 5-year period, the sales drop of Healthcare Sector giant was -3.34%. The company achieved an average annual earnings per share of 90.13%. With a float of $87.10 million, this company’s outstanding shares have now reached $89.46 million.
Travere Therapeutics Inc (TVTX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Travere Therapeutics Inc is 2.66%, while institutional ownership is 121.41%. The most recent insider transaction that took place on Nov 04 ’25, was worth 2,416,140. In this transaction SVP, CHIEF ACCOUNTING OFFICER of this company sold 67,115 shares at a rate of $36.00, taking the stock ownership to the 48,545 shares. Before that another transaction happened on Nov 04 ’25, when Company’s Officer proposed sale 67,115 for $36.00, making the entire transaction worth $2,416,140.
Travere Therapeutics Inc (TVTX) Recent Fiscal highlights
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.47 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.38) by -0.09. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.07 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 90.13% per share during the next fiscal year.
Travere Therapeutics Inc (NASDAQ: TVTX) Trading Performance Indicators
Travere Therapeutics Inc (TVTX) is currently performing well based on its current performance indicators. A quick ratio of 2.71 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.41.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.08, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach 0.83 in one year’s time.
Technical Analysis of Travere Therapeutics Inc (TVTX)
Looking closely at Travere Therapeutics Inc (NASDAQ: TVTX), its last 5-days average volume was 2.21 million, which is a jump from its year-to-date volume of 1.83 million. As of the previous 9 days, the stock’s Stochastic %D was 69.41%.
During the past 100 days, Travere Therapeutics Inc’s (TVTX) raw stochastic average was set at 97.17%, which indicates a significant increase from 93.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.74 in the past 14 days, which was higher than the 1.10 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $26.81, while its 200-day Moving Average is $20.07. However, in the short run, Travere Therapeutics Inc’s stock first resistance to watch stands at $37.33. Second resistance stands at $38.54. The third major resistance level sits at $40.33. If the price goes on to break the first support level at $34.32, it is likely to go to the next support level at $32.53. Now, if the price goes above the second support level, the third support stands at $31.32.
Travere Therapeutics Inc (NASDAQ: TVTX) Key Stats
Market capitalization of the company is 3.23 billion based on 89,472K outstanding shares. Right now, sales total 233,180 K and income totals -321,550 K. The company made 164,860 K in profit during its latest quarter, and 25,710 K in sales during its previous quarter.
